Last reviewed · How we verify
IPM514
At a glance
| Generic name | IPM514 |
|---|---|
| Sponsor | Beijing Immupeutics Medicine Technology Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. (PHASE1)
- Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPM514 CI brief — competitive landscape report
- IPM514 updates RSS · CI watch RSS
- Beijing Immupeutics Medicine Technology Limited portfolio CI